Compare VanEck Junior Gold Miners (GDXJ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Mesoblast Limited — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: VanEck Junior Gold Miners is far larger — about 4.7× Mesoblast Limited's market cap, and VanEck Junior Gold Miners is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Mesoblast Limited for 15 Days on average.
| GDXJ | MESO | |
|---|---|---|
Market Cap | $8.22B | $1.75B |
Volume | 3,212,198 | 239,027 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $20.96 |
52-Week Low | $87.56 | $13.19 |
Typical Hold Time | 41 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.91, up 1.62% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Recent news highlights multiple junior gold mining companies being added to the ETF, potentially increasing its diversification and appeal. Key financial ratios are not applicable as this is an ETF tracking an index of companies.
The outlook for GDXJ is influenced by gold price volatility and the performance of its underlying junior mining holdings. Opportunities exist if gold prices rise, boosting miner profitability, but risks include operational challenges and market sentiment shifts. Investors should weigh exposure to small-cap miners against broader market conditions.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
